[ad_1]
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) CEO David Elsley joined Steve Darling from Proactive to bring news the company has received clearance from the FDA and regulatory agencies in the U.S. Brazil and Mexico to modify the inclusion criteria for the LANCER trial to broaden the patient eligibility for enrolment.
Elsley telling Proactive the LANCER is designed to evaluate the efficacy and safety of CardiolRx and they hope to achieve over 50% patient recruitment by the end of the first half of 2022. The Company also announced plans to expand the clinical trial infrastructure to include up to an additional 20 clinical research centres.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…
In exchange for publishing services rendered by the Company on behalf of Cardiol Therapeutics named herein, including the promotion by the Company of Cardiol Therapeutics in any Content on the Site, the Company…
FOR OUR FULL DISCLAIMER CLICK HERE
[ad_2]
Source link
/cloudfront-us-east-2.images.arcpublishing.com/reuters/ARHZ5EW6L5LVVIRTRRXQNLFDWA.jpg "Alves joins Mexico’s Pumas on free transfer")
